
GPCR Stock Forecast & Price Target
GPCR Analyst Ratings
Bulls say
Structure Therapeutics Inc presents a positive outlook due to the promising results from its Phase 3 clinical trial (ACHIEVE-1) for orforglipron, which saw the stock increase by over 25%. The drug demonstrated improved gastrointestinal tolerability and significant enhancements in liver safety markers, with ALT and AST levels improving over time, which alleviated earlier concerns about liver safety. Additionally, orforglipron exhibited a favorable cardiovascular safety profile, further validating the company’s innovative approach in developing therapeutics targeting chronic diseases with unmet medical needs.
Bears say
Structure Therapeutics Inc is facing a challenging financial outlook, as it has incurred significant net losses expected to continue until at least commercialization, impacting investor confidence. The company's current enterprise value of approximately $410 million and a year-to-date share price decline of 20% indicate market skepticism regarding its pipeline potential, particularly for the diabetes and obesity markets. Moreover, despite positive data suggesting reduced safety risks with its lead candidate, aleniglipron, the comparative weight loss efficacy falling behind competitors may hinder the company's ability to secure necessary commercial partnerships to advance its objectives.
This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
GPCR Analyst Forecast & Price Prediction
Start investing in GPCR
Order type
Buy in
Order amount
Est. shares
0 shares